AQUALUNG THERAPEUTICS CORPORATION

Biotechnology ResearchArizona, United States2-10 Employees

Aqualung Therapeutics Corporation is a biotechnology research company focused on addressing severe lung inflammation that influences the progression and outcomes of both acute and chronic lung disorders. Based in Tucson, Arizona, the company operates with a small team and is advancing strategies that include a human monoclonal antibody targeting NAMPT, a mediator of inflammatory responses. By pursuing therapies for conditions such as acute lung injury, ventilator-induced lung injury, idiopathic pulmonary fibrosis, and pulmonary hypertension, ALT seeks to address an unmet medical need where existing drugs have limited disease-modifying effects.

Operating in the early stage biotechnology sector, ALT centers on an anti-inflammatory therapeutic platform aimed at mitigating life-threatening unchecked inflammation. Recent coverage notes that the company is developing a therapeutic approach that targets the eNAMPT pathway, underscoring its relevance to both inflammation and fibrotic organ injury.

Sign up for free to view info

Email Format Employee directory